Janssen Research & Development
3210 Merryfield Row
San Diego
California
92121
United States
Tel: 858-450-2000
About Janssen Research & Development
At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Website: http://www.janssenrnd.com/our-company
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
http://www.janssenlabs.com/about/overview
130 articles about Janssen Research & Development
-
Janssen R&D Release: New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management
6/13/2016
-
Janssen R&D Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma
6/10/2016
-
New Janssen R&D Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease
6/8/2016
-
ASCO2016: Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma
6/6/2016
-
Janssen R&D Release: New Phase 3 Study Findings Show STELARA Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease
5/24/2016
-
Janssen R&D Discontinues Fulranumab Phase III Program; Terminates Agreement with Amgen
4/4/2016
-
Janssen Research & Development Release: First Phase 3 Trial Of Daratumumab In Combination With Standard Therapy In Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint In Planned Interim Analysis
3/30/2016
-
Janssen Research & Development, Genentech Forge Clinical Trials Agreement
3/23/2016
-
Janssen Research & Development Disease Interception Unit Advances A Growing Venture Portfolio Focused On Intercepting Diseases Prior To Onset
3/22/2016
-
Janssen Research & Development Announces The Initiation Of Two Studies Evaluating Daratumumab (DARZALEX) And Atezolizumab In Multiple Myeloma And Solid Tumor
3/22/2016
-
Janssen Research & Development Release: STELARA Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
3/18/2016
-
Janssen Research & Development And Johnson & Johnson To Provide Webcast Presentation On The Janssen Oncology Hematologic Malignancy Portfolio
1/15/2016
-
Janssen Research & Development Release: Ibrutinib (IMBRUVICA) Significantly Improved Progression-Free And Overall Survival Versus Chlorambucil In Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/7/2015
-
Janssen Research & Development Release: Daratumumab (DARZALEX) Combined With Standard Treatment For Multiple Myeloma Produced Deep And Durable Responses In Relapsed Or Refractory Patients
12/7/2015
-
Janssen Research & Development Submits INVOKAMET XR (Canagliflozin / Metformin Hydrochloride Extended Release) for Approval by the U.S. FDA as an Adjunctive Treatment in Adults with Type 2 Diabetes
11/20/2015
-
Janssen Research & Development Addresses Challenges Of Caregiving In Alzheimer's Disease With New Healthy Minds Videos
11/10/2015
-
Janssen Research & Development Tackles Mental Health Stigma In New Healthy Minds Videos
10/8/2015
-
Janssen Research & Development Release: Phase 2b Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis
7/9/2015
-
Janssen Research & Development Release: Ibrutinib (IMBRUVICA) HELIOS Interim Analysis Study Data Show Significant Reductions In Risk Of Progression Or Death In Patients With Previously-Treated Chronic Lymphocytic Leukemia
6/1/2015
-
Janssen Research & Development Release: Data Show Daratumumab Achieved a Pronounced Overall Response Rate As A Single-Agent With Tolerable Safety Profile In Heavily Pre-Treated Multiple Myeloma Patients
6/1/2015